ALK-Abelló A/S ALK-Abelló A/S

ALK-Abelló A/S

ALK-B

주식 순위 #2396
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
주가
$36.27
시가총액
$8.05B
변동 (1일)
-0.41%
변동 (1년)
9.11%
국가
DK
거래 ALK-Abelló A/S (ALK-B)

카테고리

Healthcare
ALK-Abelló A/S (ALK-B)의 주가 이력
최고 종가: $35.34 (2026-10-01 기준)

최저 종가: $2.20 (2000-03-01 기준)
ALK-Abelló A/S의 주가 이력 (2000 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) 0.06%
2025 59.11%
2024 58.09%
2023 1.18%
2022 -44.26%
2021 35.05%
2020 52.05%
2019 69.02%
2018 21.48%
2017 -6.26%
2016 1.94%
2015 12.10%
2014 0.42%
2013 62.90%
2012 20.99%
2011 -3.28%
2010 -29.09%
2009 -18.50%
2008 -23.13%
2007 -41.96%
2006 116.04%
2005 -9.24%
2004 116.11%
2003 47.42%
2002 45.17%
2001 -23.57%
2000 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$527.18 23.62%
US
$251.29 835.90%
US
$137.83 -3.78%
AU
$890.85 9.42%
NL
$758.21 7.77%
CH